Phase I/II trial of EG 011 in patients with angina pectoris.

Trial Profile

Phase I/II trial of EG 011 in patients with angina pectoris.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 May 2012

At a glance

  • Drugs EG 011 (Primary)
  • Indications Angina pectoris
  • Focus Therapeutic Use
  • Sponsors Ark Therapeutics
  • Most Recent Events

    • 16 May 2012 The phase I dose-ranging component of the trial has completed enrolment; enrolment in the phase IIa stage of the trial is expected to begin in the third quarter of 2012 according to an Ark Therapeutics media release.
    • 18 May 2011 Recruitment into the low-dose group has been completed and several patients have been treated with the high dose, according to an Ark Therapeutics media release.
    • 28 Jan 2010 The first patient has been enrolled and treated according to an Ark Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top